Aplicació de la carpeta d'aprenentatge a la Universitat

Podeu consultar la versió castellana a recurs relacionat.Aquest treball es nodreix de les experiències d'innovació i millora docent de disciplines tan dispars con Biologia,Farmàcia, Filologia, Infermeria, Pedagogia i Química, utilitzant la carpeta d'aprenentatge com a instrument de concreció

Aplicacion de carpeta de aprendizaje en la universidad

Podeu consultar la versió catalana a recurs relacionat.Consideramos que la carpeta de aprendizaje es uno de los instrumentos didácticos que respetan una concepción integral tras la enseñanza-aprendizaje, ya que permite el desarrollo de todas las funciones del docente para enseñar, las del estudiante para aprender y las de ambos para evaluar. La perspectiva de mejora es evidente: por una parte, ofrece estrategias al profesorado y, por otra, cambia la manera de aprender por parte del alumnado. Por lo que respecta al alumnado, le ofrece la posibilidad de asumir la res-ponsabilidad de su aprendizaje, le permite integrar aquello que ya sabe con los contenidos nuevos que se le presentan y puede indagar y profun-dizar, pasando de una memorización y una repetición de información a su comprensión, y la capacidad de aplicarlos en situaciones reales. El razonamiento y la organización reflexiva están integrados en el proceso de aprendizaje, consiguiendo que el estudiante aprenda a aprender, de manera autónoma, acompañado y tutorizado por el profesorado

Aplicació de la carpeta d'aprenentatge a la Universitat

Podeu consultar la versió castellana a recurs relacionat.Aquest treball es nodreix de les experiències d'innovació i millora docent de disciplines tan dispars con Biologia,Farmàcia, Filologia, Infermeria, Pedagogia i Química, utilitzant la carpeta d'aprenentatge com a instrument de concreció

Aplicació de la carpeta d'aprenentatge a la Universitat

Podeu consultar la versió castellana a recurs relacionat.Aquest treball es nodreix de les experiències d'innovació i millora docent de disciplines tan dispars con Biologia,Farmàcia, Filologia, Infermeria, Pedagogia i Química, utilitzant la carpeta d'aprenentatge com a instrument de concreció

Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study.

BACKGROUND:Primary care is the ideal setting for early identification of patients with non-alcoholic fatty liver disease (NAFLD). NAFLD is a potentially progressive disease that may lead to cirrhosis and liver cancer but is frequently underrecognized because subjects at risk are often not evaluated. Controlled attenuation parameter (CAP) is a reliable method for non-invasive quantification of liver fat. It has the advantage of simultaneous measurement of liver stiffness (LS), an estimate of liver fibrosis. There is no information on CAP in subjects with risk factors from primary care. AIM:To investigate the prevalence of hepatic steatosis, as estimated by CAP, in subjects from the community with metabolic risk factors and correlate findings with clinical and biochemical characteristics and LS. PATIENTS AND METHODS:Population-based study of 215 subjects with metabolic risk factors without known liver disease identified randomly from a primary care center. A control group of 80 subjects matched by age and sex without metabolic risk factors was also studied. CAP and LS were assessed using Fibroscan. RESULTS:Subjects with risk factors had CAP values higher than those of control group (268±64 vs 243±49dB/m,p 280dB/m) in subjects with risk factors was 43%. In multivariate analysis, fatty liver index (FLI) and HOMA were independent predictive factors of severe steatosis. There was a direct correlation between CAP and FLI values (r = 0.52,p<0.001). Interestingly, prevalence of increased LS was 12.6% in the risk group vs 0% in the control group (p<0.001). Increased LS occurred predominantly in subjects with high CAP values. CONCLUSIONS:A high proportion of subjects with metabolic risk factors seen in primary care have severe steatosis. FLI could be used as a surrogate of CAP. Increased LS was found in a significant proportion of subjects with risk factors but not in control subjects

Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study.

BACKGROUND: Primary care is the ideal setting for early identification of patients with non-alcoholic fatty liver disease (NAFLD). NAFLD is a potentially progressive disease that may lead to cirrhosis and liver cancer but is frequently underrecognized because subjects at risk are often not evaluated. Controlled attenuation parameter (CAP) is a reliable method for non-invasive quantification of liver fat. It has the advantage of simultaneous measurement of liver stiffness (LS), an estimate of liver fibrosis. There is no information on CAP in subjects with risk factors from primary care. AIM: To investigate the prevalence of hepatic steatosis, as estimated by CAP, in subjects from the community with metabolic risk factors and correlate findings with clinical and biochemical characteristics and LS. PATIENTS AND METHODS: Population-based study of 215 subjects with metabolic risk factors without known liver disease identified randomly from a primary care center. A control group of 80 subjects matched by age and sex without metabolic risk factors was also studied. CAP and LS were assessed using Fibroscan. RESULTS: Subjects with risk factors had CAP values higher than those of control group (268±64 vs 243±49dB/m,p 280dB/m) in subjects with risk factors was 43%. In multivariate analysis, fatty liver index (FLI) and HOMA were independent predictive factors of severe steatosis. There was a direct correlation between CAP and FLI values (r = 0.52,p<0.001). Interestingly, prevalence of increased LS was 12.6% in the risk group vs 0% in the control group (p<0.001). Increased LS occurred predominantly in subjects with high CAP values. CONCLUSIONS: A high proportion of subjects with metabolic risk factors seen in primary care have severe steatosis. FLI could be used as a surrogate of CAP. Increased LS was found in a significant proportion of subjects with risk factors but not in control subjects

Prevalence of hepatic steatosis as assessed by controlled attenuation parameter (CAP) in subjects with metabolic risk factors in primary care. A population-based study.

BACKGROUND: Primary care is the ideal setting for early identification of patients with non-alcoholic fatty liver disease (NAFLD). NAFLD is a potentially progressive disease that may lead to cirrhosis and liver cancer but is frequently underrecognized because subjects at risk are often not evaluated. Controlled attenuation parameter (CAP) is a reliable method for non-invasive quantification of liver fat. It has the advantage of simultaneous measurement of liver stiffness (LS), an estimate of liver fibrosis. There is no information on CAP in subjects with risk factors from primary care. AIM: To investigate the prevalence of hepatic steatosis, as estimated by CAP, in subjects from the community with metabolic risk factors and correlate findings with clinical and biochemical characteristics and LS. PATIENTS AND METHODS: Population-based study of 215 subjects with metabolic risk factors without known liver disease identified randomly from a primary care center. A control group of 80 subjects matched by age and sex without metabolic risk factors was also studied. CAP and LS were assessed using Fibroscan. RESULTS: Subjects with risk factors had CAP values higher than those of control group (268±64 vs 243±49dB/m,p 280dB/m) in subjects with risk factors was 43%. In multivariate analysis, fatty liver index (FLI) and HOMA were independent predictive factors of severe steatosis. There was a direct correlation between CAP and FLI values (r = 0.52,p<0.001). Interestingly, prevalence of increased LS was 12.6% in the risk group vs 0% in the control group (p<0.001). Increased LS occurred predominantly in subjects with high CAP values. CONCLUSIONS: A high proportion of subjects with metabolic risk factors seen in primary care have severe steatosis. FLI could be used as a surrogate of CAP. Increased LS was found in a significant proportion of subjects with risk factors but not in control subjects